These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18773845)

  • 1. [Prescription of bisphosphonates in prostate cancer].
    Colombel M
    Prog Urol; 2008 Feb; 18(1 Suppl FMC):F5-7. PubMed ID: 18773845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.
    Saad F; Higano CS; Sartor O; Colombel M; Murray R; Mason MD; Tubaro A; Schulman C
    Clin Genitourin Cancer; 2006 Mar; 4(4):257-62. PubMed ID: 16729908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
    Lein M; Wirth M; Miller K; Eickenberg HU; Weissbach L; Schmidt K; Haus U; Stephan C; Meissner S; Loening SA; Jung K
    Eur Urol; 2007 Nov; 52(5):1381-7. PubMed ID: 17321667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
    Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
    Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
    Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bisphosphonates for osseus invasion caused by bronchial carcinoma].
    Bartl R
    Dtsch Med Wochenschr; 2008 Nov; 133(48):2530. PubMed ID: 19021088
    [No Abstract]   [Full Text] [Related]  

  • 7. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
    Saad F; Abrahamsson PA; Miller K
    BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 9. [Bone and Men's Health. Bisphosphonate therapy for prostate cancer].
    Suzuki H; Kamiya N; Yano M; Endo T; Takano M; Kawamura K; Imamoto T; Ichikawa T
    Clin Calcium; 2010 Feb; 20(2):258-66. PubMed ID: 20118519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annual zoledronic acid: is less more?
    Higano CS
    J Clin Oncol; 2007 Mar; 25(9):1026. PubMed ID: 17369565
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of bisphosphonates for bone metastasis in breast cancer].
    Yamada K; Kohno N
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():352-5. PubMed ID: 18161130
    [No Abstract]   [Full Text] [Related]  

  • 13. [The role of bisphosphonate in the treatment of bone metastases from prostate cancer].
    Sallami S; Ben Rhouma S; Cherif K; Benrais N; Horchani A
    Tunis Med; 2012 Jul; 90(7):507-11. PubMed ID: 22811222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
    Cai T; Bartoletti R
    J Clin Oncol; 2007 Aug; 25(22):3385; author reply 3385-6. PubMed ID: 17664492
    [No Abstract]   [Full Text] [Related]  

  • 15. Preservation of bone health in prostate cancer.
    Lattouf JB; Saad F
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintaining bone health in prostate cancer throughout the disease continuum.
    Saad F; Eastham J
    Semin Oncol; 2010 Jun; 37 Suppl 1():S30-7. PubMed ID: 20682370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical implications of bisphosphonate for bone metastases of prostate cancer].
    Kitagawa Y; Konaka H; Mizokami A; Namiki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():356-9. PubMed ID: 18161131
    [No Abstract]   [Full Text] [Related]  

  • 18. Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration.
    Schmitz-Dräger BJ; Weiss C; Ebert T; Dörsam J; Bismarck E
    Urol Int; 2013; 90(3):329-33. PubMed ID: 23407093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
    Green JR
    Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.